Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Bradley J Monk; Krishnansu S Tewari; Coraline Dubot; M Valeria Caceres; Kosei Hasegawa; Ronnie Shapira-Frommer; Pamela Salman; Eduardo Yañez; Mahmut Gümüş; Mivael Olivera Hurtado de Mendoza; Vanessa Samouëlian; Vincent Castonguay; Alexander Arkhipov; Cumhur Tekin; Kan Li; Allison Martin Nguyen; Matthew J Monberg; Nicoletta Colombo; Domenica Lorusso

doi:10.1016/S1470-2045(23)00052-9

Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

Bradley J Monk, Krishnansu S Tewari, Coraline Dubot, M Valeria Caceres, Kosei Hasegawa, Ronnie Shapira-Frommer, Pamela Salman, Eduardo Yañez, Mahmut Gümüş, Mivael Olivera Hurtado de Mendoza, Vanessa Samouëlian, Vincent Castonguay, Alexander Arkhipov, Cumhur Tekin, Kan Li, Allison Martin Nguyen, Matthew J Monberg, Nicoletta Colombo, Domenica Lorusso

Risultato della ricerca: Contributo in rivista › Articolo in rivista

Lingua originale	English
pagine (da-a)	392-402
Numero di pagine	11
Rivista	The Lancet Oncology
Volume	24
DOI	https://doi.org/10.1016/S1470-2045(23)00052-9
Stato di pubblicazione	Pubblicato - 2023

Keywords

N/A

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1016/S1470-2045(23)00052-9

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

Monk, B. J., Tewari, K. S., Dubot, C., Caceres, M. V., Hasegawa, K., Shapira-Frommer, R., Salman, P., Yañez, E., Gümüş, M., Hurtado de Mendoza, M. O., Samouëlian, V., Castonguay, V., Arkhipov, A., Tekin, C., Li, K., Martin Nguyen, A., Monberg, M. J., Colombo, N., & Lorusso, D. (2023). Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 24, 392-402. https://doi.org/10.1016/S1470-2045(23)00052-9

@article{caf3560f631344008b389232d7c57530,

title = "Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial",

keywords = "N/A, N/A",

author = "Monk, {Bradley J} and Tewari, {Krishnansu S} and Coraline Dubot and Caceres, {M Valeria} and Kosei Hasegawa and Ronnie Shapira-Frommer and Pamela Salman and Eduardo Ya{\~n}ez and Mahmut G{\"u}m{\"u}{\c s} and {Hurtado de Mendoza}, {Mivael Olivera} and Vanessa Samou{\"e}lian and Vincent Castonguay and Alexander Arkhipov and Cumhur Tekin and Kan Li and {Martin Nguyen}, Allison and Monberg, {Matthew J} and Nicoletta Colombo and Domenica Lorusso",

year = "2023",

doi = "10.1016/S1470-2045(23)00052-9",

language = "English",

volume = "24",

pages = "392--402",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

}

Monk, BJ, Tewari, KS, Dubot, C, Caceres, MV, Hasegawa, K, Shapira-Frommer, R, Salman, P, Yañez, E, Gümüş, M, Hurtado de Mendoza, MO, Samouëlian, V, Castonguay, V, Arkhipov, A, Tekin, C, Li, K, Martin Nguyen, A, Monberg, MJ, Colombo, N & Lorusso, D 2023, 'Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet Oncology, vol. 24, pagg. 392-402. https://doi.org/10.1016/S1470-2045(23)00052-9

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial

AU - Monk, Bradley J

AU - Tewari, Krishnansu S

AU - Dubot, Coraline

AU - Caceres, M Valeria

AU - Hasegawa, Kosei

AU - Shapira-Frommer, Ronnie

AU - Salman, Pamela

AU - Yañez, Eduardo

AU - Gümüş, Mahmut

AU - Hurtado de Mendoza, Mivael Olivera

AU - Samouëlian, Vanessa

AU - Castonguay, Vincent

AU - Arkhipov, Alexander

AU - Tekin, Cumhur

AU - Li, Kan

AU - Martin Nguyen, Allison

AU - Monberg, Matthew J

AU - Colombo, Nicoletta

AU - Lorusso, Domenica

PY - 2023

Y1 - 2023

KW - N/A

UR - http://hdl.handle.net/10807/232508

U2 - 10.1016/S1470-2045(23)00052-9

DO - 10.1016/S1470-2045(23)00052-9

M3 - Article

SN - 1470-2045

VL - 24

SP - 392

EP - 402

JO - The Lancet Oncology

JF - The Lancet Oncology

ER -

Monk BJ, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 2023;24:392-402. doi: 10.1016/S1470-2045(23)00052-9